Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COLL NYSE:OGN NASDAQ:PTCT NASDAQ:RYTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOLLCollegium Pharmaceutical$31.57+2.2%$29.30$23.23▼$42.29$1.01B0.64399,049 shs302,788 shsOGNOrganon & Co.$9.96+2.5%$9.55$8.01▼$23.10$2.59B0.64.54 million shs5.19 million shsPTCTPTC Therapeutics$47.65-0.7%$48.17$29.02▼$58.38$3.78B0.5865,435 shs1.21 million shsRYTMRhythm Pharmaceuticals$65.14-1.9%$62.90$40.61▼$69.89$4.14B2.26559,139 shs552,607 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOLLCollegium Pharmaceutical+1.75%+4.50%+2.32%+21.61%-3.98%OGNOrganon & Co.-3.33%+0.62%+1.88%-15.93%-51.57%PTCTPTC Therapeutics-1.62%-1.76%-7.96%+20.64%+55.12%RYTMRhythm Pharmaceuticals+0.94%+5.06%-2.53%+15.00%+57.02%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOLLCollegium Pharmaceutical4.1851 of 5 stars3.41.00.03.03.80.81.9OGNOrganon & Co.4.8925 of 5 stars3.34.01.73.71.73.32.5PTCTPTC Therapeutics4.2996 of 5 stars4.31.00.04.41.50.81.3RYTMRhythm Pharmaceuticals3.4416 of 5 stars2.52.00.04.32.50.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOLLCollegium Pharmaceutical 2.75Moderate Buy$43.7538.58% UpsideOGNOrganon & Co. 2.50Moderate Buy$18.0080.72% UpsidePTCTPTC Therapeutics 2.67Moderate Buy$65.0036.41% UpsideRYTMRhythm Pharmaceuticals 3.00Buy$78.0719.85% UpsideCurrent Analyst Ratings BreakdownLatest COLL, RYTM, PTCT, and OGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/7/2025RYTMRhythm PharmaceuticalsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$88.006/26/2025RYTMRhythm PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$84.006/17/2025PTCTPTC TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$80.005/29/2025RYTMRhythm PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$78.00 ➝ $94.005/27/2025PTCTPTC TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$68.00 ➝ $74.005/22/2025OGNOrganon & Co.BNP ParibasSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/15/2025OGNOrganon & Co.Piper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$24.00 ➝ $18.005/9/2025COLLCollegium PharmaceuticalPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$36.00 ➝ $37.005/9/2025PTCTPTC TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$55.00 ➝ $68.005/8/2025PTCTPTC TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$56.00 ➝ $42.005/7/2025PTCTPTC TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$57.00 ➝ $58.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOLLCollegium Pharmaceutical$631.45M1.61$12.83 per share2.46$7.10 per share4.45OGNOrganon & Co.$6.40B0.40$4.93 per share2.02$1.83 per share5.44PTCTPTC Therapeutics$806.78M4.68N/AN/A($14.24) per share-3.35RYTMRhythm Pharmaceuticals$130.13M31.85N/AN/A$0.35 per share186.11Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOLLCollegium Pharmaceutical$69.19M$1.2225.885.24N/A6.61%99.08%15.14%8/6/2025 (Estimated)OGNOrganon & Co.$864M$2.883.462.661.0211.92%227.43%7.34%8/5/2025 (Estimated)PTCTPTC Therapeutics-$363.30M$6.517.32N/AN/A33.56%-78.56%32.11%8/6/2025 (Estimated)RYTMRhythm Pharmaceuticals-$260.60M-$2.81N/AN/AN/A-123.26%-739.62%-44.27%8/5/2025 (Estimated)Latest COLL, RYTM, PTCT, and OGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025OGNOrganon & Co.$0.93N/AN/AN/A$1.55 billionN/A8/5/2025Q2 2025RYTMRhythm Pharmaceuticals-$0.64N/AN/AN/A$43.72 millionN/A5/8/2025Q1 2025COLLCollegium Pharmaceutical$1.50$1.49-$0.01$0.07$174.96 million$177.76 million5/7/2025Q1 2025RYTMRhythm Pharmaceuticals-$0.69-$0.81-$0.12-$0.81$40.43 million$37.72 million5/6/2025Q1 2025PTCTPTC Therapeutics$0.85$10.04+$9.19N/A$437.16 million$1.18 billion5/1/2025Q1 2025OGNOrganon & Co.$0.89$1.02+$0.13$0.33$1.53 billion$1.51 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOLLCollegium PharmaceuticalN/AN/AN/AN/AN/AOGNOrganon & Co.$0.080.80%N/A2.78%N/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/ALatest COLL, RYTM, PTCT, and OGN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/2/2025OGNOrganon & Co.quarterly$0.020.8%5/12/20255/12/20256/12/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOLLCollegium Pharmaceutical3.301.081.01OGNOrganon & Co.16.491.671.15PTCTPTC TherapeuticsN/A3.893.85RYTMRhythm PharmaceuticalsN/A3.303.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOLLCollegium PharmaceuticalN/AOGNOrganon & Co.77.43%PTCTPTC TherapeuticsN/ARYTMRhythm PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipCOLLCollegium Pharmaceutical2.51%OGNOrganon & Co.1.40%PTCTPTC Therapeutics5.50%RYTMRhythm Pharmaceuticals6.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOLLCollegium Pharmaceutical21032.13 million31.33 millionOptionableOGNOrganon & Co.4,000259.96 million256.32 millionNot OptionablePTCTPTC Therapeutics1,41079.26 million74.90 millionOptionableRYTMRhythm Pharmaceuticals14063.62 million59.74 millionOptionableCOLL, RYTM, PTCT, and OGN HeadlinesRecent News About These CompaniesRhythm Pharmaceuticals To Announce Topline Results from Phase 2 Trial Evaluating Oral MC4R Agonist Bivamelagon in Acquired Hypothalamic Obesity2 hours ago | globenewswire.comAt the Altar Lyrics by Elevation Rhythm & Anna Golden3 hours ago | gigwise.comGRhythm of Resistance3 hours ago | msn.comLeerink Partners Initiates Coverage of Rhythm Pharmaceuticals (RYTM) with Outperform RecommendationJuly 8 at 10:36 AM | msn.comRhythm Pharmaceuticals (NASDAQ:RYTM) Coverage Initiated by Analysts at Leerink PartnersJuly 8 at 3:51 AM | americanbankingnews.comLeerink Partners Initiates Coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM)July 7 at 8:51 AM | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Consensus Recommendation of "Buy" from AnalystsJuly 7 at 2:15 AM | marketbeat.comCardiac Rhythm Remote Monitoring Devices Market Grows to USD 8.8B by 2035, CAGR at 5.3%July 4, 2025 | pharmiweb.comPNPSL: Bristol Rhythm's halftime lead, playoff hopes vanish in 6-3 loss to Charlottetowne HopsJuly 4, 2025 | heraldcourier.comHCall Super Unveils Mix CD for Dekmantel, ‘A Rhythm Protects One’July 4, 2025 | thequietus.comTInsider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Sells 1,319 Shares of StockJuly 4, 2025 | insidertrades.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Alastair Garfield Sells 1,319 SharesJuly 3, 2025 | marketbeat.comRhythm Pharmaceuticals Inc News (RYTM) - Investing.comJuly 2, 2025 | investing.comAdcock, Chiefs blank Rhythm to win 5th straightJuly 1, 2025 | wpsdlocal6.comWNPSL: Bristol Rhythm fall on the road, close out season with two home games this weekJune 30, 2025 | heraldcourier.comHThe UniverSoul Circus brings its 'Rhythm of the World' tour to National HarborJune 30, 2025 | wusa9.comWOf Wood, Worship And Wonder: Rhythm Wagholikar On The Rath Yatra TraditionJune 28, 2025 | msn.comRhythm & Food community BBQJune 28, 2025 | kxnet.comKRhythm & Roots unveils artist schedule, puts single-day tickets on saleJune 28, 2025 | heraldcourier.comHRhythm & Rally offer pickleball for Neurodivergent kidsJune 28, 2025 | 41nbc.com4Rhythm Pharmaceuticals (NASDAQ:RYTM) Earns Market Outperform Rating from JMP SecuritiesJune 28, 2025 | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseTesla Bulls and Bears Collide: What Investors Should KnowBy Sam Quirke | June 18, 2025View Tesla Bulls and Bears Collide: What Investors Should KnowCOLL, RYTM, PTCT, and OGN Company DescriptionsCollegium Pharmaceutical NASDAQ:COLL$31.57 +0.67 (+2.17%) As of 04:00 PM EasternCollegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.Organon & Co. NYSE:OGN$9.96 +0.24 (+2.47%) Closing price 03:59 PM EasternExtended Trading$9.98 +0.02 (+0.25%) As of 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.PTC Therapeutics NASDAQ:PTCT$47.65 -0.33 (-0.69%) Closing price 04:00 PM EasternExtended Trading$48.15 +0.50 (+1.05%) As of 04:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Rhythm Pharmaceuticals NASDAQ:RYTM$65.14 -1.25 (-1.88%) Closing price 04:00 PM EasternExtended Trading$67.20 +2.06 (+3.16%) As of 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Is Fortinet Ready to Break Out After Months of Consolidation? AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Sizzling Insider Buys for Your High-Yield Watchlist Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
